Syros Pharmaceuticals: Despite High-Demand Treatments, We Remain Cautious

Based in Watertown, Massachusetts, Syros Pharmaceuticals (Nasdaq: SYRS) is a biopharmaceutical company that is developing treatments to control genes in patients with cancer, immune-mediated diseases, and other illnesses.

SYRS initially offered 4.0 million shares at an expected price range of $14 to $16.

Lead Underwriters: Cowen & Company and Piper Jaffray

Underwriters: JMP Securities and Wedbush Securities

Business Summary: Biopharmaceutical Developing Treatments to Control Genes in Certain Diseases

Syros Pharmaceuticals is a biopharmaceutical company that is developing treatments, which control genes involved in cancer and additional immune-mediated diseases. Its proprietary platform identifies gene control targets, which have been linked to genomically-defined patient segments. The platform also identifies potential new drug targets in a range of diseases, allows users to advance a wave of medications with a potential to affect multiple drivers of disease via a single target, and provides a lens for diagnosing and categorizing patients, including those with multi-factorial and complex diseases.

The company's drug pipeline includes sY-145, a selective RARa agonist for subsets of patients who suffer from acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The pipeline also includes SY-1365, a selective CDK7 inhibitor for acute leukemia.

Source: Syros

As an alternative to many current treatments, gene control therapies target alterations in the cell's underlying gene expression.

Use of Proceeds: Primarily For Additional Clinical Trials

Syros Pharmaceuticals intends to use the net proceeds from the IPO to fund a Phase 2 clinical trial for SY-1425 in AML and MDS, a Phase ½ clinical trial for SY1365, and preclinical programs. Any remaining funds will be used for working capital and general corporate purposes.

Executive Management: Impressive Academic, Industry Credentials

1 2 3
View single page >> |

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.